Phase 1 N=6 Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Transitional Cell Carcinoma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=28 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects
Pharmacokinetics
Primary: Part 1: Maximum Observed Plasma Concentration (Cmax) of Apremilast — 205; 273; 373 ng/mL
Phase 1 N=60 Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 129; 207; 202; 290 ng/mL
Phase 1 N=36 A Study of Lasmiditan in Healthy Chinese Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity AUC(0-∞) of Lasmiditan — 385; 829; 1990 nanogram*hour per milliliter…
Phase 1 N=28 A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants
Elderly Study Participants · Adult Study Participants
Primary: The Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil (PSL) — 903.6; 838.4 ng/mL
Phase 1 N=40 A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity
Hallux Valgus Deformity
Primary: Surgical Site Assessment — 0; 0; 0; 0 Number of skin reactions
Phase 1 N=40 Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects
Healthy Adults
Primary: Incidence of Adverse Events (AEs) [Safety and Tolerability] — 2; 4; 3; 6 Participants
Phase 1 N=100 Safety Study of OPC-12759 Ophthalmic Solution
Dry Eye Syndromes
Primary: Number of Subjects With Blurred Vision After Instillation — 0; 10; 0; 21 participants
Phase 1 N=84 A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects
Healthy Adult Male
Primary: Maximum Plasma Concentration (Cmax) of Tolvaptan — 131; 149; 125; 203 ng/mL
Phase 1 N=27 Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Advanced Solid Tumors
Primary: Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) — 0…
Phase 1 N=12 Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
Myotonic Dystrophy, Type 1 (DM1) · Myotonic Dystrophy
Primary: Incidence of Adverse Events, Serious Adverse Events, and Drug-related Adverse Events [Safety and Tolerability] After a Single Dose of ERX-963 vs. Placebo — 0; 0; 1; 1…
Phase 1 N=30 Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)
Therapeutic Equivalency
Primary: Maximum Observed Plasma Concentration (Cmax) — 15.49; 17.35 ng/mL — p=0.3008
Phase 1 N=46 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Gastrointestinal Stromal Tumors (GIST) · Other Relapsed or Refractory Solid Tumors
Primary: Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib — 0; 0; 0; 0 patients with event(s) of dose-limiting
Phase 1 N=1 Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Neurofibromatoses
Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001
Phase 1 N=20 Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and…